Loading
Virus Internalization / Host-directed Therapy · Journal article
Virulence · May 27, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing current knowledge on host factors mediating CHIKV infection, viral lifecycle mechanisms, immune regulation, and emerging antiviral strategies. It provides expert interpretation of CHIKV-host interactions and evaluates druggability of host-directed therapeutic targets, but does not report original experimental or clinical evidence.
Narrative review. Populations affected by CHIKV infection globally; review does not report data on a specific enrolled or studied cohort.
CHIKV case fatality rate is low (~0.1–0.13%), but approximately 50% of patients develop persistent arthralgia/arthritis lasting months to years In the past 20 years, CHIKV has caused over 10 million cases across more than 125 countries or regions From January to July 2025, approximately 240,000 cases of CHIKF and 90 CHIKF-related deaths were reported across 16 countries and regions worldwide
Druggability assessment of host-directed targets described qualitatively without systematic comparison of efficacy or safety across candidate drugs No specific antiviral drug against CHIKV is yet available; FDA-approved vaccine Ixchiq was halted on 22 August 2025 due to serious safety concerns
Clinicians and researchers should use this review to understand CHIKV pathogenesis mechanisms and host-directed therapeutic targets under development. The absence of approved antivirals and recent vaccine safety concerns underscore the urgent need for alternative therapeutic strategies informed by improved understanding of virus-host interactions.
This is a comprehensive narrative review synthesizing current knowledge on CHIKV host factors and therapeutic strategies, providing expert perspective on pathogenesis mechanisms and drug development approaches without reporting original experimental data or clinical trial results.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should use this review to understand CHIKV pathogenesis mechanisms and host-directed therapeutic targets under development. The absence of approved antivirals and recent vaccine safety concerns underscore the urgent need for alternative therapeutic strategies informed by improved understanding of virus-host interactions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing acute fever, rashes, and even acute or chronic arthralgia/arthritis. With its expanding global distribution, CHIKV represents a significant public health threat, yet no specific antivirals are approved. The lifecycle of CHIKV is highly dependent on interactions with host factors that mediate viral entry, genome replication, protein translation, assembly, and release. A deeper understanding of these host factors provides new insights into CHIKV pathogenesis and offers strategies to overcome drug resistance associated with high viral mutation rates. This review summarizes and updates current knowledge on the roles of host factors in CHIKV infection, systematically dissects the interaction network and cell-type specificity of key host factors, critically evaluates the druggability of host-directed therapeutic targets, and outlines recent progress in anti-CHIKV drug development, with a focus on strategies targeting both viral proteins and host dependencies, placing a particular emphasis on host-directed antiviral therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.